Louis Pasteur

Lady Mireille and Sir Dennis Gillings Global Public Health Fellowships advance the next generation of leaders

Retrieved on: 
Tuesday, July 25, 2023
KCMG, Biobank, University, Friends, Virology, Louis Pasteur, Public, Teaching, COVID-19, Infection, Institut Pasteur Korea, Medicine, Research, Concordia University, University of North Carolina at Pembroke, International Network of Health Promoting Hospitals and Health Services, Doctor of Philosophy, Science, Entrepreneurship, Neuroscience, Laboratory, FRS, Faculty, Knowledge, Neurology, Pasteur Institute, Microbiology, Disease, Pharmaceutical industry, Nursing, Management

NEW YORK, and PARIS, July 25, 2023 /PRNewswire/ -- The Pasteur Foundation US and the Institut Pasteur are pleased to announce that the 2023 cohort of Lady Mireille and Sir Dennis Gillings Global Public Health Fellowships have been conferred.

Key Points: 
  • NEW YORK, and PARIS, July 25, 2023 /PRNewswire/ -- The Pasteur Foundation US and the Institut Pasteur are pleased to announce that the 2023 cohort of Lady Mireille and Sir Dennis Gillings Global Public Health Fellowships have been conferred.
  • The fellowships, the vision of Lady Mireille Gillings, are curated by an unprecedented group of international partners made up of the University of Cambridge, the University of North Carolina Gillings School of Global Public Health and Concordia University, Montreal.
  • "Future leaders in public health must have skills across what I call the 3Ms: management, money and medicine," said Lady Mireille Gillings, "The fellowships are designed to build business acumen on top of scientific experience, which is critical for the next generation of global scientists."
  • "The Lady Mireille and Sir Dennis Gillings Global Public Health Fellowships are funded and supported by visionary leadership from Lady Mireille Gillings.

Lady Mireille and Sir Dennis Gillings Global Public Health Fellowships advance the next generation of leaders

Retrieved on: 
Tuesday, July 25, 2023
KCMG, Biobank, University, Friends, Virology, Louis Pasteur, Public, Teaching, COVID-19, Infection, Institut Pasteur Korea, Medicine, Research, Concordia University, University of North Carolina at Pembroke, International Network of Health Promoting Hospitals and Health Services, Doctor of Philosophy, Science, Entrepreneurship, Neuroscience, Laboratory, FRS, Faculty, Knowledge, Neurology, Pasteur Institute, Microbiology, Disease, Pharmaceutical industry, Nursing, Management

NEW YORK, and PARIS, July 25, 2023 /PRNewswire/ -- The Pasteur Foundation US and the Institut Pasteur are pleased to announce that the 2023 cohort of Lady Mireille and Sir Dennis Gillings Global Public Health Fellowships have been conferred.

Key Points: 
  • NEW YORK, and PARIS, July 25, 2023 /PRNewswire/ -- The Pasteur Foundation US and the Institut Pasteur are pleased to announce that the 2023 cohort of Lady Mireille and Sir Dennis Gillings Global Public Health Fellowships have been conferred.
  • The fellowships, the vision of Lady Mireille Gillings, are curated by an unprecedented group of international partners made up of the University of Cambridge, the University of North Carolina Gillings School of Global Public Health and Concordia University, Montreal.
  • "Future leaders in public health must have skills across what I call the 3Ms: management, money and medicine," said Lady Mireille Gillings, "The fellowships are designed to build business acumen on top of scientific experience, which is critical for the next generation of global scientists."
  • "The Lady Mireille and Sir Dennis Gillings Global Public Health Fellowships are funded and supported by visionary leadership from Lady Mireille Gillings.

SpikImm, a Biotech Company Founded by Truffle Capital and Institut Pasteur, Announces That Its Monoclonal Antibody Neutralises All SARS-COV-2 Variants of Concern, Including Omicron (BA.1 and BA.2)

Retrieved on: 
Wednesday, April 13, 2022
Research, Infectious Diseases, Finance, Consulting, Clinical Trials, Professional Services, Biotechnology, Pharmaceutical, Health, Science, Partnership, CEO, Immunodeficiency, Foundation, Developmental biology, Institut Pasteur Korea, Delta, Lymphatic system, Microbiology, Pre-exposure prophylaxis, Vichy, Biotechnology, Research, Genomics, Acceleration, MD, Medicine, Therapy, Education, Severe acute respiratory syndrome coronavirus 2, Patient, Biomedical Research, Nobel Prize, Financial technology, Infection, Vaccination, AIDS, Medtech, List of life sciences, Neurodegeneration, Innovation, Degenerative disease, Hugo, Chief executive officer, Louis Pasteur, Public health, EUA, Multimedia, HIV, Pasteur Institute, Science, Cancer, Digital technology, Vaccine, Pharmaceutical industry, Neutralizing antibody, COVID19, Omicron

SpikImm expects to initiate clinical trials mid-2022 and then, to demonstrate the medical benefit in a phase 2 in immunocompromised patients.

Key Points: 
  • SpikImm expects to initiate clinical trials mid-2022 and then, to demonstrate the medical benefit in a phase 2 in immunocompromised patients.
  • SPK001 was selected among hundreds of screened anti-SARS-CoV-2 monoclonals, and cross-neutralizes all SARS-CoV-2 variants of concern including Delta, Omicron BA.1 and BA.2.
  • SpikImm was founded by Truffle Capital and Institut Pasteur to develop human monoclonal antibodies (mAbs) to prevent COVID19 infection.
  • In 2019, Truffle Capital has announced the raising of nearly 400 million in new institutional funds, including 250 million in BioMedTech.

Tampa General Hospital Continues Its Master Facility Plan with Completion of a New Central Energy Plant

Retrieved on: 
Monday, March 21, 2022
State, Forbes, GE Healthcare, Natural gas, Fast Track, Tampa General Hospital, Percussion section, Adult, News, Hillsborough Community College, Hospital, Home, CEO, Louis Pasteur, Woman, Artificial intelligence, Health, Technology, United States Environmental Protection Agency, Natural Resources, Physician, EPA, Cooking, Trauma, U.S. News & World Report, Eye, Efficiency, TGH, John F. Kennedy Boulevard, Education, Patient, Sterilization, Renewable energy, Medicine, John Couris

TAMPA, Fla., March 21, 2022 /PRNewswire/ -- As an essential feature of its $550 million master facility plan, Tampa General Hospital has opened its new 16,000-square-foot central energy plant. Specially constructed to provide a reliable, protected power supply to the 1,041-bed hospital, the central energy plant has built-in redundancies to seamlessly support Tampa General during major storms or other disruptions to electric service.

Key Points: 
  • The new $53 million central energy plant is part of Tampa General's comprehensive master facility plan.
  • TAMPA, Fla., March 21, 2022 /PRNewswire/ --As an essential feature of its $550 million master facility plan, Tampa General Hospital has opened its new 16,000-square-foot central energy plant.
  • Specially constructed to provide a reliable, protected power supply to the 1,041-bed hospital, the central energy plant has built-in redundancies to seamlessly support Tampa General during major storms or other disruptions to electric service.
  • Our new central energy plant can accommodate our electrical power needs now and into the future," said John Couris, president and CEO of Tampa General.

Ring Therapeutics Announces the Appointment of Industry Leaders to its Board of Directors

Retrieved on: 
Thursday, March 17, 2022
Rubius, Stanford Law School, Twitter, Therapy, MBA, MD, Islamic Society of North America, COO, University, Doctor of Philosophy, GLOBE, Novartis, Patient, Record, Board of directors, Flagship Pioneering, Ring, Louis Pasteur, BS, Cooley, Biochemistry, Marketing, SRL Diagnostics, MidOcean Partners, Ionis Pharmaceuticals, Benevolence, Rutgers University College, Business, Board, Saint Joseph University, Leadership, Tissue, Columbia University Graduate School of Journalism, Growth, Degenerative disease, Harvard University, Drug development, LLP, Cooley LLP, NPS, Rhône-Poulenc, JD, Management, Ionis, Pharmacy, Medicine

All have exceptional proven track records of pioneering in the biotech and pharmaceutical industries and bring a wealth of expertise and experience to Ring.

Key Points: 
  • All have exceptional proven track records of pioneering in the biotech and pharmaceutical industries and bring a wealth of expertise and experience to Ring.
  • Dr. Nader joins Rings Board with extensive experience in the biotech industry and currently serves as chairman of Talaris Therapeutics, Benevolent AI and Neurvati Biosciences, as board director of Moderna, and as senior advisor of Blackstone Life Sciences.
  • Mr. Epstein brings more than 25 years of extensive drug development, leadership, and commercialization experience to Rings Board of Directors.
  • Ring Therapeutics is revolutionizing the programmable medicine space by harnessing the most abundant and diverse member of the human commensal virome, anelloviruses.

T.H.A.C Announces the Acquisition of an International Patent on Its Drug Candidate ALF-5755 For the Early Treatment of Type 2 Diabetes Mellitus and Relative to the Gut Microbiota Composition

Retrieved on: 
Monday, September 27, 2021
Health, Diabetes, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, THAC, Patent, Infection, EADS, University, Peripheral neuropathy, Public sector, Roy Taylor (scientist), French Government of the Hundred Days, COVID-19, Pandemic, Ageing, Dysbiosis, Patient, ADA, Louis Pasteur, Lists of diseases, CSIS, INRA, Diabetes, Disease, CEO, Industry, Acquisition, University of Paris, Company, Growth, Microbiota, University of South Florida, Science, Global Virus Network, Human, Travancore–Cochin, Research, Obesity, Insulin, Hospital, Â, Sanofi, Insulin resistance, R, SA, Doctor of Philosophy, INSERM, Degenerative disease, Pharmaceutical industry, Management

This patent protects the drug candidate of THAC and its use for the protection of oxygen sensitive bacteria, for example in the gut microbiota.

Key Points: 
  • This patent protects the drug candidate of THAC and its use for the protection of oxygen sensitive bacteria, for example in the gut microbiota.
  • It allows to reinforce our robust patent portfolio as well as to develop a competitive oral formulation for our product.
  • With this patent, we accelerate our development, and we strengthen our competitive position on the market.
  • The dysbiosis, disequilibrium of the gut flora in humans, is characterized by complex changes in the microbiota and its various micro-organisms.

Spikimm and Institut Pasteur Announce That SPKM001, A Next-generation, Highly Potent Anti-SARS-CoV-2 Human Monoclonal Antibody, Effectively Neutralizes the Delta and Delta Plus Variants

Retrieved on: 
Wednesday, September 8, 2021
Science, Other Science, Biotechnology, Research, Pharmaceutical, Health, Infectious Diseases, Other Health, SpikImm, Truffle Capital, the Institut Pasteur and Pasteur Network, SPIKIMM, TRUFFLE CAPITAL, THE INSTITUT PASTEUR AND PASTEUR NETWORK

SPKM001 is a high affinity human monoclonal antibody which targets the receptor-binding site (RBD) on the SARS-CoV-2 Spike protein.

Key Points: 
  • SPKM001 is a high affinity human monoclonal antibody which targets the receptor-binding site (RBD) on the SARS-CoV-2 Spike protein.
  • SpikImm has recently signed an exclusive worldwide license agreement with the Institut Pasteur for the development of anti-SARS-CoV-2 (Covid-19) monoclonal antibodies (mAbs), including SPKM001.
  • Delta Plus, which the World Health Organization also lists as a variant of concern, was first detected in the U.K. in June.
  • It has since been found in several other countries, including the U.S., India, China, Russia, and Japan.

ImaBiotech Supports the Institut Pasteur de Lille and Apteeus for the Development of Covid-19 Therapy

Retrieved on: 
Monday, June 28, 2021
University of Lille Nord de France, Pasteur Institute, National academies, COVID-19 pandemic in France, Louis Pasteur, LILLE, Learned societies, Academia, Institut Pasteur Korea

The high molecular specificity of Mass Spectrometry Imaging, combined with rapid method development highlighted the added value of this technique over other technologies.

Key Points: 
  • The high molecular specificity of Mass Spectrometry Imaging, combined with rapid method development highlighted the added value of this technique over other technologies.
  • The next step is to demonstrate the medical value through a clinical trial, sponsored by the Institut Pasteur de Lille and led by Professor Benoit Deprez.
  • Institut Pasteur de Lille is a private, non-profit foundation with recognized public utility status since 1898.
  • As an international center for biomedical research, Institut Pasteur de Lille focuses on Longevity fundamental research, education and public health to ensure we live better for longer.

Translate Bio Announces First Quarter 2021 Financial Results and Provides Corporate Update

Retrieved on: 
Thursday, May 6, 2021
Sanofi, Companies, Health, CAC 40, Vaccine, Louis Pasteur, Sanofi–Translate Bio COVID-19 vaccine

Translate Bio received a $25 million payment from Sanofi Pasteur based on achievement of this milestone.

Key Points: 
  • Translate Bio received a $25 million payment from Sanofi Pasteur based on achievement of this milestone.
  • Interim results from this trial are expected in the third quarter of 2021.
  • Translate Bio also believes its technology may apply broadly to a wide range of diseases, including diseases that affect the liver.
  • Translate Bio is also pursuing the development of mRNA vaccines for infectious diseases under a collaboration with Sanofi Pasteur.

Global Non-Thermal Pasteurization Market (2020 to 2026) - Government Investment in Food Processing Machinery & Equipment Presents Opportunities

Retrieved on: 
Friday, February 12, 2021
Food science, Industrial processes, Food and drink, Louis Pasteur, Pasteurization, Articles, Economic sectors, Food industry, Food, Food irradiation

Non-thermal pasteurization technologies have been proven to reduce food processing time and energy consumption as compared to traditional thermal technologies.

Key Points: 
  • Non-thermal pasteurization technologies have been proven to reduce food processing time and energy consumption as compared to traditional thermal technologies.
  • Based on technique, the HPP segment is estimated to account for the largest share in the non-thermal pasteurization market in 2020.
  • Hence, rising acceptance among food product manufacturers and high market penetration have enabled HPP to have the largest market share.
  • The food industry widely uses non-thermal pasteurization for the preservation of meat, seafood, fruits, and vegetable products as well as other packaged food products.